<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508413</url>
  </required_header>
  <id_info>
    <org_study_id>K030-120</org_study_id>
    <nct_id>NCT04508413</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function</brief_title>
  <official_title>An Exploratory, 14-week, Open-label Clinical Food Study to Evaluate the Effects of KB295 in Adult Patients With Ulcerative Colitis (UC) Presenting With Mild-to-moderate UC Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleido Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleido Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory, open-label clinical study aims to explore the effects of KB295, a novel&#xD;
      glycan, on adult patients with ulcerative colitis (UC) presenting with mild-to-moderate UC&#xD;
      symptoms&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing any treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day -1 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing discontinuations due to adverse events (AEs)</measure>
    <time_frame>Day -1 to Day 84</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>KB295</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>KB295</intervention_name>
    <description>KB295 is a novel glycan</description>
    <arm_group_label>KB295</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be male or female, ≥18 and ≤75 years of age&#xD;
&#xD;
          -  Confirmed diagnosis of UC (&gt;6 months) by endoscopy&#xD;
&#xD;
          -  Mild-to-moderate UC with at least 4 weeks of UC symptomatology prior to screening&#xD;
&#xD;
          -  Stable medication regimen for at least 2 weeks prior to screening, if on medication&#xD;
             for UC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Possible or confirmed diagnosis of Crohn's disease or indeterminate disease&#xD;
&#xD;
          -  History of isolated distal proctitis&#xD;
&#xD;
          -  Use of any antidiarrheal medications within the last 1 week prior to screening&#xD;
&#xD;
          -  Antibiotic treatment within the past 28 days prior to screening&#xD;
&#xD;
          -  Any non-UC related immunosuppressive medications other than purine analogs. Systemic&#xD;
             corticosteroids including prednisone &gt; 10 mg per day are excluded.&#xD;
&#xD;
          -  Major intra-abdominal surgery related to the bowel within 24 weeks prior to the&#xD;
             screening period and/or planned invasive surgery/hospitalization during the study&#xD;
&#xD;
          -  Major medical comorbidities, or other conditions in the opinion of the PI, that might&#xD;
             impact the patient's safety or compliance, or the interpretation of the study results&#xD;
&#xD;
          -  Treatment with any other investigational drugs within 28 days prior to the screening&#xD;
             visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaleido Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elligo Health Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <zip>T23 R50R</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Kaleido</keyword>
  <keyword>Kaleido Biosciences</keyword>
  <keyword>KB295</keyword>
  <keyword>Oligosaccharide</keyword>
  <keyword>Glycan</keyword>
  <keyword>Pathogens</keyword>
  <keyword>Microbiome metabolic therapy</keyword>
  <keyword>MMT</keyword>
  <keyword>Mild-to-moderate UC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

